I Tried Retatrutide – Here's What Happened

Key wellness & self-care / productivity takeaways

• Understand why retatrutide can feel “paradoxical”

  • It appears to act on three pathways, not one:
    • GLP-1 → reduces appetite (less hunger)
    • GIP (mentioned as part of prior drugs like tirzepatide) → affects fuel partitioning/energy handling
    • Glucagon receptor activation → increases energy expenditure/metabolic rate (“burn more”)
  • Because these effects may not hit at the same time or equally, people can experience:
    • More hunger yet still losing weight (metabolic boost outruns appetite suppression early on)
    • Less hunger with stronger appetite suppression (for others, GLP-1 dominates sooner)

• Be cautious: monitor cardiovascular/physiologic signals

  • The presenter reports:
    • Resting heart rate increased ~50%
    • Heart rate variability decreased
    • Core temperature increased (~1.2°F)
  • Wellness takeaway: treat increased heart rate/HRV changes as a “needs study / worth tracking” signal, not something to ignore.

• Don’t outsource fundamentals to drugs

  • Labs and experience suggested sleep disruption may drive inflammation, even if the medication isn’t directly “inflammatory.”
  • Self-care emphasis:
    • Sleep consistency matters (even short-term disruption may raise inflammatory markers like hs-CRP).
    • Nutrition and activity still matter—the drug doesn’t replace them.

• Track outcomes beyond the scale (biomarkers + performance)

  • The presenter tracked 127 biomarkers pre/post using a health app.
  • Reported stability in many systems (thyroid, cortisol, blood sugar, blood counts).
  • Notable changes:
    • hs-CRP increased (possible downstream effect of poorer sleep)
    • LDL cholesterol and ApoB decreased (unexpected benefit)
  • Wellness strategy: use directional lab monitoring and watch trends, not just weight.

• Muscle/lean-mass concerns may be more nuanced than headlines suggest

  • The video addresses an “anecdote vs trial data” mismatch:
    • Clinical trials suggest ~38% of weight loss is lean mass.
    • Some users claim muscle sparing on DEXA.
  • Proposed explanation (hypothesis):
    • Glucagon-related signaling may increase FGF21, which could protect against muscle loss
    • But response may depend on FGF21 resistance in obesity vs higher sensitivity in leaner individuals.
  • Practical takeaway:
    • Strength/performance may matter more than a single imaging metric.
    • “Lean mass loss” on DEXA may not equal “functional muscle loss.”

• Reframe “should you come off?” as a control question, not a moral one

  • The presenter shares a friend’s experience with Mounjaro:
    • Lost a lot of weight, felt great, assumed they must stop
  • Presenter suggestion: you may not necessarily need to discontinue if it works well for you.
  • Wellness/productivity takeaway: consider medication as ongoing biology management, potentially not just a temporary “weight loss patch,” depending on goals, tolerance, and clinician guidance.

• Broader health framing: benefits may extend beyond weight

  • The video claims emerging signals for potential improvements in:
    • Heart health
    • Joint health
    • Liver health
    • Possible neuroprotective effects (not solely tied to weight loss)

Presenters / sources mentioned

• Nick (the video’s primary narrator/presenter; referred to as “Nick”)
• Andrew Huberman (mentioned as discussing muscle-sparing speculation)
• FDA-approved 503A compounding pharmacy (source of retatrutide for the presenter; specific name not provided)
• 100 Health app / “Stay Curious Metabolism” newsletter (tools/channels used by the presenter)
• GLP-1 drug trials / DEXA (referenced as evidence sources, not a specific publication named in the subtitles)
• Repatha (PCSK9 inhibitor; mentioned as a drug class example)
• Pinealon (another peptide mentioned by the presenter for sleep recovery; referenced as an aside)